Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies based on its Alluminox™ technology platform, which has been shown to induce rapid and selective cell killing and tumor necrosis. Our lead product ASP-1929 is conditionally approved and commercially available in Japan and is currently being evaluated in a global phase 3 clinical study. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives.